Abstract 2274
Background
Cetuximab is crucial in the management of squamous cell carcinoma of the head and neck (SCCHN) patients. Grade 3-4 infusion reactions (IRs) occur in 2% of colorectal cancer (ASPECCT study, ∼1000 pts). Despite the 2.7% IR rate in the EXTREME trial (NEJM 2008), higher rates were reported in small series of SCCHN (6-10%). There is an urgent need to better appraise the natural history and the predictive factors for IRs in HNSCC pts exposed to Cetuximab.
Methods
The medical records from all consecutive SCCHN patients (n = 451) treated by cetuximab at Gustave Roussy (Cancer Campus Grand Paris) from January 2013 to December 2015 were reviewed. IR severity was defined as per the NCI-CTCAE v4.0. The impact of potential risk factors was analyzed (history of allergy, biological and clinicopathological variables).
Results
All patients analyzed received pre-medication including corticosteroids and antihistamines. Out of 441 patients, 34 patients (7.5%) presented grade 3-4 IR, nearly all of them requiring intensive care unit referral. Most of the IRs occurred during the first cycle (range: 1-3). The occurrence of grade 3-4 IR was associated with prior allergy history (P
Conclusions
In real life, grade 3-4 IR consecutive to cetuximab appears far more common (7.5%) than reported in prospective trials. This is the largest series of patients ever focusing on the risk of IR induced by cetuximab in SCCHN pts. History of prior allergy is a strong predictor of IR and could be used to better allocate treatment and supervise pts. Further prospective data are however required to confirm this.
Clinical trial identification
Gustave Roussy, Université Paris-Saclay, Villejuif, F-94805, France
Legal entity responsible for the study
Gustave Roussy, Université Paris-Saclay, Villejuif, France
Funding
Gustave Roussy, Université Paris-Saclay, Villejuif, France
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract